Poplar Therapeutics Closes $45 million Series A Extension to Advance Development of Lead Program, PHB-050, A New Class of Anti-IgE Therapy for Multiple Atopic Conditions
Extension financing adds new investors, Janus Henderson Investors and RA Capital, with strong renewed participation from existing investors Proceeds will support further clinical development of lead program PHB-050 in food allergy and other atopic conditions…
